XERS earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E 118.36. Updated 2026-07-23.
Xeris Biopharma Holdings (XERS) Research Hub
Xeris Biopharma Holdings (XERS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.45 USD (-3.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 118.36, market cap 1.46B. This hub links to the full technical, earnings and options research available for XERS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.45 USD (-3.37%) |
| 52-week range | 6.74 USD – 9.02 USD |
| Trend regime | Range |
| 14-day RSI | 41.1 (Bearish) |
| Trailing P/E | 118.36 |
| Market cap | 1.46B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for XERS
Covered Call on XERS: how it works, illustrative setup around the real 7.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XERS: how it works, illustrative setup around the real 7.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XERS: how it works, illustrative setup around the real 7.45 USD price, max profit/loss, breakeven and when to use it. Educational.
XERS technical analysis: range, last 7.45 USD, RSI 41.1, 52w range 6.74 USD–9.02 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is XERS in?
Xeris Biopharma Holdings (XERS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is XERS in an uptrend or downtrend?
As of 2026-09-11, XERS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XERS's trailing P/E ratio?
XERS's trailing P/E is 118.36, with a market cap of 1.46B. See the earnings research page for full valuation detail.
When does XERS next report earnings?
XERS is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of 0.02 USD.